Regeneron reiterated at outperform by RBC

RBC Capital Markets analyst Jason Kantor rated Regeneron Pharmaceuticals, Inc. at outperform, above average risk, with a $25 price target, on continued confidence in VEGF-Trap in the multi-billion dollar markets of cancer and AMD. According to Kantor, VEGF-Trap has the potential to be as good or better than Avastin or Lucentis. Investors could build positions in Regeneron ahead of key catalysts including positive phase 2 data. Shares of the Tarrytown, N.Y.-based biotechnology company were up $2.44, or 11.74%, at $23.22. (Nasdaq: REGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.